Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal

Transplantation

Volumn 92, Issue 7, 2011, Pages 767-773

  Heilman, Raymond L ^a   Younan, Kerrie ^b   Wadei, Hani M ^b   Mai, Martin L ^b   Reddy, Kunam S ^a   Chakkera, Harini A ^a   Gonwa, Thomas A ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Kidney transplantation; Randomized trial; Sirolimus; Steroid avoidance; Tacrolimus

Indexed keywords

CHOLESTEROL; CREATININE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOPENIA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; TUBULAR ATROPHY;

ADRENAL CORTEX HORMONES; ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 80053297344     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822805d7     Document Type: Review

References (23)

1. Meier-Kriesche H-U, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
2. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
3. Cosio FG, Grande JP, Larson TS, et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 1130.
4. Gonwa TA, Hricik DE, Brinker K, et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560.
5. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure1,2,10. Transplantation 2001; 72: 777.
6. Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 2003; 75: 1213.
7. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070.
8. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883.
9. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
10. Dean PG, Grande JP, Sethi S, et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation 2008; 85: 1212.
11. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation.NEngl J Med 2007; 357: 2562.
12. Anil Kumar MS, Heifets M, Fyfe B, et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005; 80: 807.
13. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression. A 5-year experience. Am J Transplant 2005; 5: 2473.
14. Opelz G, Dohler B, Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005; 5: 720.
15. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
16. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
17. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604.
18. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522.
19. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115.
20. Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled spare-the-nephron trial. Kidney Int 2011; 79: 897.
21. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurininhibitor- free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet. 2011; 377: 837.
22. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
23. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN2). Am J Transplant 2007; 7: 518.